Outcomes in localized prostate cancer: National prostate cancer register of Sweden follow-up study

Journal of the National Cancer Institute

Volumn 102, Issue 13, 2010, Pages 950-958

  Stattin, Pär ^a   Holmberg, Erik ^b   Johansson, Jan Erik ^d   Holmberg, Lars ^e   Adolfsson, Jan ^f   Hugosson, Jonas ^c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CAUSE OF DEATH; CLINICAL PRACTICE; COMORBIDITY; DYING; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SOCIAL STATUS; SWEDEN; WATCHFUL WAITING; ADJUVANT THERAPY; BLOOD; EPIDEMIOLOGY; HEALTH SURVEY; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; REGISTER; RETROSPECTIVE STUDY; SOCIOECONOMICS; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMORBIDITY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; REGISTRIES; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SELECTION BIAS; SOCIOECONOMIC FACTORS; SWEDEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954741591     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq154     Document Type: Article

References (36)

1. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98(16):1134-1141.
2. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specifc antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878.
3. Shao YH, Demissie K, Shih W, et al. Contemporary risk profle of prostate cancer in the United States. J Natl Cancer Inst. 2009;101(18): 1280-1283.
4. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004;5(2):101-106.
5. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8):1650-1659.
6. Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol. 2005;47(1):16-21. (Pubitemid 39575713)
7. Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred defnitive therapy. J Urol. 2004;171(4):1520-1524.
8. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23(32):8165-8169.
9. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178(6):2359-2364.
10. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13): 1320-1328.
11. Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100(16):1144-1154.
12. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11): 1202-1209.
13. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notifed cancer cases recorded on death certifcates in 1978. Acta Radiol Oncol. 1984;23(5):305-313.
14. Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register-a sample survey for year 1998. Acta Oncol. 2009;48(1):27-33.
15. Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol. 2007;41(6):456-477.
16. Regional Oncological Center. The National Prostate Cancer Register (NPCR) in Sweden 2002-2006. Uppsala, Sweden: Regional Oncological Center, Uppsala-Örebro; 2008. http://www.roc.se/prostata/rapport/rapport-02-06.pdf. Accessed September 1, 2009.
17. Sobin, LH. Urological tumours. In: Wittekind C, ed. TNM Classifcation of Malignant Tumours. 6th ed. (UICC). New York, NY: Wiley-Liss; 2002:184-187.
18. Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, ed. Urologic Pathology. Philadelphia, PA: Lea & Febiger; 1997:171-198.
19. Stattin P, Holmberg E, Bratt O, et al. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol. 2008;180(6):2423-2429; discussion 2429-2430.
20. Lagerlund M, Bellocco R, Karlsson P, et al. Socio-economic factors and breast cancer survival-a population-based cohort study (Sweden). Cancer Causes Control. 2005;16(4):419-430.
21. Swedish SSI. Socioeconomic index (SEI). Meddelanden i samordnings-frågor. 1982;4 Nytryck 1984.
22. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294.
23. Sundararajan V, Quan H, Halfon P, et al; International Methodology Consortium for Coded Health Information (IMECCHI). Cross-national comparative performance of three versions of the ICD-10 Charlson index. Med Care. 2007;45(12):1210-1215
24. National Board of Health and Welfare. Quality and content of the National Patient Register. Discharges from in-patient care 1964-2006 and attendance in out-patient care (excluding primary health care) 1997-2006. (In Swedish.). 2009. http://www.socialstyrelsen.se/NR/rdonlyres/3FE3 2D5A-E276-4AE0-8FB9- 67A4F4B497F4/10193/20081251-rev.pdf. Accessed September 1, 2009.
25. Choudhury JB. Nonparametric confdence interval estimation for competing risks analysis: application to contraceptive data. Stat Med. 2002;21(8):1129-1144.
26. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
27. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data. Stat Med. 1993; 12(8):737-751.
28. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Ass. 1999;94(445):496-509.
29. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515-526. doi:10.1093/biomet/81.3.51.
30. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349(9056): 906-910.
31. StataCorp. Stata Statistical Software: Release 10.0. College Station, TX: Stata Corporation;, 2008.
32. Giordano SH, Kuo YF, Duan Z, et al. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008;112(11): 2456-2466.
33. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43(4):316-381.
34. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-448.
35. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176(4, pt 1):1415-1419.
36. Fall K, Stromberg F, Rosell J, et al. Reliability of death certifcates in prostate cancer patients. Scand J Urol Nephrol. 2008;42(4):352-357.